ARIDIS PHARMACEUTICALS INC (ARDS) Stock Price, Forecast & Analysis
NASDAQ:ARDS • US0403341045
ARDS Key Statistics, Chart & Performance
The current stock price of ARDS is 0.3101 USD. In the past month the price increased by 22.81%. In the past year, price decreased by -72.31%.
ARDS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ARDS. When comparing the yearly performance of all stocks, ARDS is a bad performer in the overall market: 84.97% of all stocks are doing better.
ARDS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARDS. Both the profitability and financial health of ARDS have multiple concerns.
ARDS Financial Highlights
Over the last trailing twelve months ARDS reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 53.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARDS Forecast & Estimates
8 analysts have analysed ARDS and the average price target is 10.2 USD. This implies a price increase of 3189.26% is expected in the next year compared to the current price of 0.3101.
For the next year, analysts expect an EPS growth of 71.9% and a revenue growth 1609.12% for ARDS
ARDS Ownership
ARDS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARDS
Company Profile
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company is headquartered in Los Gatos, California and currently employs 37 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The firm's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
Company Info
ARIDIS PHARMACEUTICALS INC
983 University Avenue, Bldg. B
Los Gatos CALIFORNIA 95032 US
CEO: Vu Truong
Employees: 37
Phone: 14083851742.0
ARIDIS PHARMACEUTICALS INC / ARDS FAQ
What does ARIDIS PHARMACEUTICALS INC do?
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company is headquartered in Los Gatos, California and currently employs 37 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The firm's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
What is the current price of ARDS stock?
The current stock price of ARDS is 0.3101 USD. The price increased by 17.91% in the last trading session.
Does ARIDIS PHARMACEUTICALS INC pay dividends?
ARDS does not pay a dividend.
How is the ChartMill rating for ARIDIS PHARMACEUTICALS INC?
ARDS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for ARDS stock?
8 analysts have analysed ARDS and the average price target is 10.2 USD. This implies a price increase of 3189.26% is expected in the next year compared to the current price of 0.3101.
Can you provide the sector and industry classification for ARIDIS PHARMACEUTICALS INC?
ARIDIS PHARMACEUTICALS INC (ARDS) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ARDS stock?
ARIDIS PHARMACEUTICALS INC (ARDS) has a market capitalization of 11.23M USD. This makes ARDS a Nano Cap stock.